Dementia
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
On Market (5)
Approved therapies currently available
Competitive Landscape
37 companies ranked by most advanced pipeline stage
+7 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 34,845 patients across 50 trials
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
The Effect of Rasagiline on Cognition in Parkinson's Disease
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Delta-THC in Behavioral Disturbances in Dementia
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)
Building Better Caregivers Online: An Online Workshop for Caregivers of Those With Traumatic Brain Injury, Post Traumatic Stress Disorder, or Alzheimer's or Other Dementia
BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)
Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)
Study of Depakote for Behavioral and Psychological Symptoms in Dementia
Dyadic, App-supported Collaborative Care Intervention Trial for Family Caregivers of People Living With Dementia
Decision Aid for Dementia Therapies
The INSPIRE Study: Intervention Strategies for Preserving Intellectual Resilience and Engagement
Sing Out Loud: a Choral Singing Program for Persons Living with Dementia
VR&R: Providing Caregiver Respite by Managing BPSDs and Improving QoL in People with Dementia Using Immersive VR-Therapy
You, Me and Nature Pilot Study
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
Forest Bathing Intervention for Persons Living with Dementia and Family Carers
Companion Robotic Pets and Older Adults
Training Social and Health Care prOfessionals in mUsic-based Therapeutic iNterventions to Support Older People With Dementia
A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD)
The Care Ecosystem Consortium Effectiveness Study
A Global Approach to Tackle Cognitive Decline
VRx@Home: Study to Evaluate VR-therapy for PwD Living at Home
Advance Care Planning (ACP) in Primary Care for Dementia
Remote Cognitive Multidomain Assessment in People With Cognitive Disorders
An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living
REmote Assessment and Dynamic Response Intervention II
Using Technology to Support Care Partners for Persons With Alzheimer's Disease: Tele-STELLA
REmote Assessment and Dynamic Response Intervention
Multidisciplinary Expert System for the Assessment & Management of Complex Brain Disorders
Assessing Acceptability, Cost, and Efficacy of STELLA-Support Via Technology
PUMCH Dementia Longitudinal Cohort Study
Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort
Feasibility of the SmartPrompt for Improving Everyday Function in Dementia
Autologous Stem/Stromal Cells in Neurological Disorders and Disease
Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia
D-CARE - The Dementia Care Study: A Pragmatic Clinical Trial of Health System-Based Versus Community-Based Dementia Care
Evaluating the Impact of VR-therapy on BPSD and QoL of Individuals With Dementia Admitted to Hospital
Development and Evaluation of the DEA App
Effect of a Dyadic Multisensory and Cognitive Stimulation Program for People With Dementia and Their Caregivers
Pilot Study Person-centred Tablet Intervention
The Impact of Art Therapy on the Relationships Between Individuals Diagnosed With Alzheimer's Disease and Their Care Partners
Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial
Automated Brain Morphometry for Dementia Diagnosis
IDEA Study Cognitive Stimulation Therapy (CST) Trial in Tanzania
IDEA Study Cognitive Stimulation Therapy (CST) Trial in Nigeria
Related Jobs in Neurology
Corporate Strategy Intern
Promotional Materials Review Committee Manager
Director, Human Resources
Director/Senior Director, CMC, Drug Substance
Associate Director, Operational Procurement
Sales Support Representative (Temp-to-Hire)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.